Trofinetide (Daybue)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses Trofinetide (Daybue), 200 mg/mL, solution, oral or by gastrostomy tube. Indication: For the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older and weighing at least 9 kg.